Breakthrough in Thyroid Cancer Research: New Prognostic Model and Immunotherapy Strategy Unveiled

Tianjin Medical University Cancer Institute and Hospital researchers have made a significant discovery in the field of thyroid cancer by developing a novel classifier and prognostic model based on the stemness characteristics of thyroid cancer patients. Utilizing transcriptomic data from The Cancer Genome Atlas (TCGA) database, the team identified three distinct subtypes of thyroid cancer, with subtype III exhibiting lower overall survival and a higher somatic mutational burden. Their research highlights the critical role of the DPYSL3 gene in tumor progression and immune microenvironment, paving the way for a new strategy in thyroid cancer immunotherapy.

Key Takeaways:

• Researchers at Tianjin Medical University Cancer Institute and Hospital developed a novel classifier and prognostic model based on stemness characteristics of thyroid cancer patients.
• The study identified three distinct subtypes of thyroid cancer, with subtype III exhibiting lower overall survival and a higher somatic mutational burden.
• The DPYSL3 gene was found to promote the proliferation, migration, and invasion of thyroid cancer cells and is associated with cancer stem cell properties.
• A prognostic model was constructed using key genes and machine learning algorithms, revealing that patients in the high-risk group may benefit more from immune checkpoint blockade therapy.
• The study suggests that the stemness-based classification and prognostic modeling can provide a new strategy for thyroid cancer immunotherapy.

Statistics:

• The study analyzed transcriptomic data from 516 thyroid carcinoma patients in The Cancer Genome Atlas (TCGA) database.
• Subtype III exhibited significantly lower overall survival (OS) and a higher somatic mutational burden compared to other subtypes.
• The DPYSL3 gene was found to be associated with cancer stem cell properties and was identified as a critical regulator of tumor progression.

Sources:

• Identification of stemness subtypes and prognostic modeling in thyroid cancer: the critical role of DPYSL3 in tumor progression and immune microenvironment. Discover Oncology, 2025,16(1):1-20.
• Tianjin Medical University Cancer Institute and Hospital
• National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer
• The Cancer Genome Atlas (TCGA) database
• NewsRx. Tianjin Medical University Cancer Institute and Hospital Researchers Focus on Thyroid Cancer (Identification of stemness subtypes and prognostic modeling in thyroid cancer: the critical role of DPYSL3 in tumor progression and immune ...). Immunotherapy Weekly. July 2, 2025; p 4223.